Allergy Therapeutics' Peanut Allergy Study Gives Positive Primary Results

By Anthony O. Goriainoff

Allergy Therapeutics PLC said Tuesday that a study evaluating biomarkers from peanut-allergic patients gave positive primary results.

The U.K. biotechnology company said that its peanut allergy vaccine candidate, which is based on virus-like particles, had a successful primary outcome, and that the results confirmed the peanut vaccine candidate's hypoallergic potential.

The company said the results were encouraging and provided strong support for the human translation of the pre-clinical results, as well as strong confidence in the data to be generated in its planned Phase I study, which is due to start on the first quarter of 2022.

The results further strengthen the company's Investigational New Drug application with the U.S. Food and Drug Administration, which it expects to submit later in the year.

"Through our collaboration with Imperial College London and the dedication of our clinical and R&D teams at Allergy Therapeutics, we are another step closer to offering a potentially transformative treatment option for one of the most dangerous allergies," Chief Executive Manuel Llobet said.

Shares at 0750 GMT were up 1.40 pence, or 5.2%, at 28.25 pence.

Write to Anthony O. Goriainoff at [e-mail]

(END) Dow Jones Newswires

August 03, 2021 04:07 ET (08:07 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.